VGX-1027 displays immunomodulatory and anti-inflammatory activities by inhibiting toll-like receptor 4 (TLR4) signaling. In diabetic mice, VGX-1027 decreases synthesis of pro-inflammatory cytokines and improves glomerulosclerosis. In other animal models, this compound inhibits antigen presentation, preventing the development of systemic lupus erythematosus (SLE), increases survival rates and improving overall pathology.

References


Caution: This product is intended for laboratory and research use only. It is not for human or drug use.